Any current/future new fundraising through debt or equity?

During Q2 FY23, Balaxi Pharmaceuticals completed issuance of equity shares and warrants aggregating to INR 49.61 crore on a preferential basis. The proceeds from this equity fundraising are planned to partly finance the new EU-GMP-compliant manufacturing facility. No specific mention of new or future debt fundraising was made in the transcript. Bank limits and potential cost overruns related to the new plant were questioned, but no detailed disclosure on new debt or additional equity beyond the mentioned preferential issue was provided.

Any current/future capex/capital investment/strategic investment?

Balaxi Pharmaceuticals is setting up an EU-GMP compliant pharmaceutical manufacturing unit near Hyderabad. Groundbreaking for the plant is scheduled for December 12, 2022. The commissioning of the unit is targeted for March 2024. This plant is a backward integration project aimed at reducing product costs. Post commissioning, the plant is expected to gain EU-GMP approval within about six months, enabling entry into new markets in Southeast Asia, Central Africa, and Latin America. The new facility will support manufacturing of Oral Solid Dosages and Liquid Injectables. Capital raised includes I

Future growth expectations in sales/revenue/volumes?

Revenues for Q2 stood at INR 86.40 crore, with 23% quarter-on-quarter growth, driven by strong volume growth in Latin America. Strong expansion expected in established markets like the Dominican Republic and Guatemala. Nascent markets such as Honduras and El Salvador are anticipated to scale up revenues in coming quarters. Over 745 product registrations currently active in six countries; 646 new registrations submitted or in pipeline. Launch of new products planned leading to further improvements in all covered countries. EU-GMP compliant manufacturing unit commissioning targeted for March 202

Future growth expectations in earnings/operating earnings/profits/EPS?

FY24-25: Expected increase in profitability and volumes due to commissioning of EU-GMP compliant plant. New plant will enable backward integration, reducing product costs and improving delivery control. EU-GMP approval anticipated ~6 months post-commissioning will open new markets in Southeast Asia, Central Africa, and Latin America. Quality advantage of EU-GMP compliance expected to command 3%-4% better pricing. Direct revenue benefits from new plant expected to start from FY25-26. Q2 FY23 PAT rose 28.5% YoY to INR 15.50 crore; EPS for the quarter at INR 15.49. Sustained growth driven by stro

Balaxi PharmaQ2 FY23Pharmaceuticals & Biotechnology

Balaxi Pharma Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹21.76P/E: 49.4Market Cap: ₹120 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Revenues for Q2 stood at INR 86.40 crore, with 23% quarter-on-quarter growth, driven by strong volume growth in Latin America.
Strong expansion expected in established markets like the Dominican Republic and Guatemala.
Nascent markets such as Honduras and El Salvador are anticipated to scale up revenues in coming quarters.
Over 745 product registrations currently active in six countries; 646 new registrations submitted or in pipeline.
Launch of new products planned leading to further improvements in all covered countries.
EU-GMP compliant manufacturing unit commissioning targeted for March 2024 will boost backward integration and open new markets in Southeast Asia, Central Africa, and Latin America.
Expected profitability and volumes to increase from FY24-25, with direct revenue benefits from the plant starting FY25-26.
Anticipated price advantage of 3%-4% due to improved quality and regulatory certifications.

Margin guidance

Category 3

FY24-25: Expected increase in profitability and volumes due to commissioning of EU-GMP compliant plant.
New plant will enable backward integration, reducing product costs and improving delivery control.
EU-GMP approval anticipated ~6 months post-commissioning will open new markets in Southeast Asia, Central Africa, and Latin America.
Quality advantage of EU-GMP compliance expected to command 3%-4% better pricing.
Direct revenue benefits from new plant expected to start from FY25-26.
Q2 FY23 PAT rose 28.5% YoY to INR 15.50 crore; EPS for the quarter at INR 15.49.
Sustained growth driven by strong volume growth in Latin American markets and ongoing product launches.
EBITDA margin improved to 17.1%, reflecting scaling in newer geographies and cost absorption.

See what Balaxi Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

During Q2 FY23, Balaxi Pharmaceuticals completed issuance of equity shares and warrants aggregating to INR 49.61 crore on a preferential basis.
The proceeds from this equity fundraising are planned to partly finance the new EU-GMP-compliant manufacturing facility.
No specific mention of new or future debt fundraising was made in the transcript.
Bank limits and potential cost overruns related to the new plant were questioned, but no detailed disclosure on new debt or additional equity beyond the mentioned preferential issue was provided.

Order book

Yes

The transcript does not specifically mention the current or expected order book or pending orders in exact numbers. However, relevant information includes: - Balaxi Pharmaceuticals currently has 745 product registrations in six countries. - There are 646 new registrations submitted or in the pipeline to be submitted to various health departments in different countries. - The company is expecting significant scale-up in revenues from nascent markets like Honduras and El Salvador in coming quarters. - The new EU-GMP compliant manufacturing plant will enable expansion into new markets (Southeast Asia, Central Africa, Latin America) after approval, potentially increasing order flow and revenues from FY24-25 onwards. No explicit orderbook or pending order values are disclosed in the available transcript.

See what Balaxi Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes

Balaxi Pharmaceuticals is setting up an EU-GMP compliant pharmaceutical manufacturing unit near Hyderabad.
Groundbreaking for the plant is scheduled for December 12, 2022.
The commissioning of the unit is targeted for March 2024.
This plant is a backward integration project aimed at reducing product costs.
Post commissioning, the plant is expected to gain EU-GMP approval within about six months, enabling entry into new markets in Southeast Asia, Central Africa, and Latin America.
The new facility will support manufacturing of Oral Solid Dosages and Liquid Injectables.
Capital raised includes INR 49.61 crore through equity and warrants on a preferential basis to partly finance the EU-GMP compliant facility.
Construction tenders and detailed designing are underway as of November 2022.
The investment is expected to improve profitability, volume, and market presence starting FY24-25 and yield revenue benefits from FY25-26 onwards.

Track Balaxi Pharma — get its next earnings analysis in your feed

How does Balaxi Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBalaxi Pharma

Rev 2Mar 3

See where Balaxi Pharma sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Balaxi Pharma rank in Pharmaceuticals & Biotechnology?

Compare Balaxi Pharma against every Pharmaceuticals & Biotechnology company (Q2 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Balaxi Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →